Pharmaceutical company Breckenridge Pharmaceutical Inc revealed on Monday the receipt of US Food and Drug Administration final approval for its Abbreviated New Drug Application for Rivastigmine Transdermal System in 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours strengths.
The Rivastigmine Transdermal System in 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours strength is the generic for Exelon Patch by Novartis. Breckenridge plans to launch the product with immediate effect.
Rivastigmine Transdermal System was developed in collaboration with Welding GMBH & Co KG, SK Chemicals Co Ltd and Breckenridge.
For the 12 months ending 30 September 2019, the Exelon Patch and its therapeutic equivalents generated annual sales of USD161m according to industry sales data.
Dr Reddy's Laboratories unveils Bortezomib for Injection 3.5 mg/vial in the US
Breckenridge wins FDA final approval for Rivastigmine Transdermal System ANDA
Amneal to unveil generic Revatio and Amicar Tablets in the US market
Breckenridge wins final FDA approval for launch of generic Tarceva
Sandoz signs binding agreement to acquire Aspen Global's Japanese business
Mizner Bioscience awarded FDA approval for generic anti-anxiety medicine for dogs
Microbion's lead antimicrobial given generic name Pravibismane
Primex Pharmaceuticals names new global commercial head
JAMA Oncology Publishes Analysis of Patients with Prior Gastrectomy Treated with Lonsurf